<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01090414</url>
  </required_header>
  <id_info>
    <org_study_id>101-99</org_study_id>
    <nct_id>NCT01090414</nct_id>
  </id_info>
  <brief_title>An Extension Study for Subjects Who Are Deriving Benefit With Idelalisib (GS-1101; CAL-101) Following Completion of a Prior Idelalisib Study</brief_title>
  <official_title>An Extension Study to Investigate the Safety and Durability of Clinical Activity of Idelalisib in Subjects With Hematologic Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gilead Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a long-term safety extension study of idelalisib (GS-1101; CAL-101) in patients with
      hematologic malignancies who complete other idelalisib studies. It provides the opportunity
      for patients to continue treatment as long as the patient is deriving clinical benefit.
      Patients will be followed according to the standard of care as appropriate for their type of
      cancer. The dose of idelalisib will generally be the same as the dose that was administered
      at the end of the prior study, but may be titrated up to improve clinical response or down
      for toxicity. Patients will be withdrawn from the study if they develop progressive disease,
      unacceptable toxicity related to idelalisib, or if they no longer derive clinical benefit in
      the opinion of the investigator.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date type="Actual">March 22, 2010</start_date>
  <completion_date type="Actual">June 18, 2018</completion_date>
  <primary_completion_date type="Actual">June 18, 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Response Rate</measure>
    <time_frame>Parent study baseline to end of study 101-99 (maximum: up to 91.2 months)</time_frame>
    <description>Overall response rate (ORR) was defined as the percentage of participants who achieve complete response (CR), partial response (PR), or minor response (MR; for lymphoplasmacytic lymphoma/Waldenström's macroglobulinemia (LPL/WM) only).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Who Experienced Any Treatment-Emergent Adverse Events</measure>
    <time_frame>Parent study baseline to end of study 101-99 (maximum: up to 91.2 months) plus 30 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of Response</measure>
    <time_frame>Parent study baseline to end of study 101-99 (maximum: up to 91.2 months)</time_frame>
    <description>Duration of response (DOR) was defined as the interval from the first documentation of CR, PR, or MR (for LPL/WM) to the earlier of the first documentation of disease progression or death from any cause. DOR was analyzed using Kaplan-Meier (KM) estimates.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival</measure>
    <time_frame>Parent study baseline to end of study 101-99 (maximum: up to 91.2 months)</time_frame>
    <description>Progression-free survival (PFS) was defined as the interval from start of idelalisib treatment in the parent study to the earlier of the first documentation of disease progression or death from any cause. PFS was analyzed using KM estimates.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>Parent study baseline to end of study 101-99 (maximum: up to 91.2 months)</time_frame>
    <description>Overall survival (OS) was defined as the interval from the start of study treatment in the parent study to death from any cause. OS was analyzed using KM estimates.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Response</measure>
    <time_frame>Parent study baseline to end of study 101-99 (maximum: up to 91.2 months)</time_frame>
    <description>Time to response (TTR) was defined as the interval from start of study treatment to the first documentation of CR, PR, or MR (for LPL/WM). Analysis only includes participants who achieved complete or partial response (or minor response for LPL/WM participants). No participants in the 101-02 (AML and MM) groups achieved a complete or partial response.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">202</enrollment>
  <condition>Chronic Lymphocytic Leukemia</condition>
  <condition>Lymphoma, Non-Hodgkin</condition>
  <arm_group>
    <arm_group_label>Idelalisib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive up to 350 mg of idelalisib twice daily until disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Idelalisib</intervention_name>
    <description>Idelalisib tablets or capsules administered orally</description>
    <arm_group_label>Idelalisib</arm_group_label>
    <other_name>Zydelig®</other_name>
    <other_name>GS-1101</other_name>
    <other_name>CAL-101</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Patients with hematologic malignancies completing a prior idelalisib study with a
             clinical benefit are eligible

          -  Women of childbearing potential must have a negative pregnancy test to be eligible

          -  Male patients, and female patients of childbearing potential, must agree to use
             method(s) of contraception specified in the protocol

        Key Exclusion Criteria:

          -  Patients who are unwilling or unable to comply with the protocol are not eligible

        Note: Other protocol defined Inclusion/Exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gilead Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Gilead Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clearview Cancer Institute</name>
      <address>
        <city>Huntsville</city>
        <state>Alabama</state>
        <zip>35805</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095-1678</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford Cancer Center</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304-5548</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Cancer &amp; Blood Disorders, PC</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Long Island Jewish medical Center</name>
      <address>
        <city>New Hyde Park</city>
        <state>New York</state>
        <zip>11042</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Weill Medical College of Cornell</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Sinai School of Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Ohio State University Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Willamette Valley Cancer Institute and Research Center</name>
      <address>
        <city>Springfield</city>
        <state>Oregon</state>
        <zip>97477</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer and Research Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yakima Regional Cancer Care</name>
      <address>
        <city>Yakima</city>
        <state>Washington</state>
        <zip>98902</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792-5156</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Barrientos J, Coutre SE, et al. (2014). Long-Term Follow-Up of a Phase 1 Trial of Idelalisib (ZYDELIG®) in Combination with Bendamustine, Bendamustine/Rituximab, Fludarabine, Chlorambucil, or Chlorambucil/Rituximab in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) [Abstract 3343]. 56th American Society of Hematology (ASH) Annual Meeting and Exposition, San Francisco, California.</citation>
  </results_reference>
  <results_reference>
    <citation>Barrientos JC, Leonard JP, et al. (2013). Update on a Phase 1 Study of the Selective PI3Kδ Inhibitor, Idelalisib (GS-1101) in Combination with Rituximab and/or Bendamustine in Patients with Relapsed or Refractory CLL [Presentation]. American Society for Clinical Oncology (ASCO) Annual Meeting, Chicago, Illinois.</citation>
  </results_reference>
  <results_reference>
    <citation>Barrientos JC, Wagner-Johnston ND, et al. (2013). Chemo-Immunotherapy Combination of Idelalisib with Bendamustine/Rituximab or Chlorambucil/Rituximab in Patients with Relapsed/ Refractory CLL Demonstrates Efficacy and Tolerability [Poster 4176]. 55th ASH Annual Meeting and Exposition, New Orleans, Louisiana.</citation>
  </results_reference>
  <results_reference>
    <citation>Barrientos JC, Sharman J, et al. (2012). GS-1101 (CAL-101), A Selective Phosphatidylinositol 3-Kinase-Delta Inhibitor, in Combination With Ofatumumab for the Treatment of Relapsed/ Refractory CLL [Abstract 1062]. Haematologica: the Hematology Journal 17th Congress of the European Hematology Association 14-17 June 2012 Amsterdam; Netherlands 97 (Suppl 1): 433.</citation>
  </results_reference>
  <results_reference>
    <citation>Benson D, Kahl BS, et al. (2013). Final Results of a Phase 1 Study of Idelalisib, a Selective Inhibitor of PI3Kδ, in Patients with Relapsed or Refractory Indolent non-Hodgkin Lymphoma [Presentation]. ASCO Annual Meeting, Chicago, Illinois.</citation>
  </results_reference>
  <results_reference>
    <citation>Brown JR, Cheson BD, et al. (2015). Patterns of Lymphocytosis in Patients with CLL or Small Lymphocytic Lymphoma (SLL) Treated with Idelalisib. 57th ASH Annual Meeting and Exposition, Orlando, Florida.</citation>
  </results_reference>
  <results_reference>
    <citation>Brown JR, Byrd JC, Coutre SE, Benson DM, Flinn IW, Wagner-Johnston ND, Spurgeon SE, Kahl BS, Bello C, Webb HK, Johnson DM, Peterman S, Li D, Jahn TM, Lannutti BJ, Ulrich RG, Yu AS, Miller LL, Furman RR. Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia. Blood. 2014 May 29;123(22):3390-7. doi: 10.1182/blood-2013-11-535047. Epub 2014 Mar 10.</citation>
    <PMID>24615777</PMID>
  </results_reference>
  <results_reference>
    <citation>Brown JR, Furman RR, et al. (2013). Final Results of a Phase 1 Study of Idelalisib (GS-1101) a Selective Inhibitor of Phosphatidylinositol 3-Kinase p110 Delta (PI3Kδ) in Patients with Relapsed or Refractory CLL [Presentation]. ASCO Annual Meeting, Chicago, Illinois.</citation>
  </results_reference>
  <results_reference>
    <citation>Coutre SE, Flinn IW, de Vos S, Barrientos JC, Schreeder MT, Wagner-Johnson ND, Sharman JP, Boyd TE, Fowler N, Dreiling L, Kim Y, Mitra S, Rai K, Leonard JP, Furman RR. Idelalisib in Combination With Rituximab or Bendamustine or Both in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia. Hemasphere. 2018 Apr 25;2(3):e39. doi: 10.1097/HS9.0000000000000039. eCollection 2018 Jun.</citation>
    <PMID>31723767</PMID>
  </results_reference>
  <results_reference>
    <citation>Coutre S, Barrientos C, et al. (2015). Safety of Idelalisib in B-cell Malignancies: Integrated Analysis of Eight Clinical Trials. ASCO Annual Meeting, Chicago, Illinois.</citation>
  </results_reference>
  <results_reference>
    <citation>Coutre S, Leonard J, et al. (2015). Idelalisib Monotherapy Results in Durable Responses in Patients with Relapsed or Refractory Waldenstrom's Macroglobulinemia. ASCO Annual Meeting, Chicago, Illinois.</citation>
  </results_reference>
  <results_reference>
    <citation>DeVos S, Wagner-Johnston ND, et al. (2014). Durable Responses Following Treatment with the PI3K-Delta Inhibitor Idelalisib in Combination with Rituximab, Bendamustine, or Both, in Recurrent Indolent non-Hodgkin Lymphoma: Phase I/II Results [Abstract 3063]. 56th ASH Annual Meeting and Exposition, San Francisco, California.</citation>
  </results_reference>
  <results_reference>
    <citation>DeVos S, Furman RR, et al. (2013). Idelalisib, a Selective Inhibitor of PI3Kδ, in Combination with Bendamustine, Fludarabine, or Chlorambucil in Patients with Relapsed or Refractory (R/R) CLL [Poster 2878]. 55th ASH Annual Meeting and Exposition, New Orleans, Louisiana.</citation>
  </results_reference>
  <results_reference>
    <citation>Flinn IW, Kahl BS, Leonard JP, Furman RR, Brown JR, Byrd JC, Wagner-Johnston ND, Coutre SE, Benson DM, Peterman S, Cho Y, Webb HK, Johnson DM, Yu AS, Ulrich RG, Godfrey WR, Miller LL, Spurgeon SE. Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-δ, as therapy for previously treated indolent non-Hodgkin lymphoma. Blood. 2014 May 29;123(22):3406-13. doi: 10.1182/blood-2013-11-538546. Epub 2014 Mar 10.</citation>
    <PMID>24615776</PMID>
  </results_reference>
  <results_reference>
    <citation>Furman R, DeVos S, et al. (2014). Long-Term Follow-Up of a Phase 1 Study of Idelalisib (ZYDELIG®) in Combination with Anti-CD20 Antibodies (Rituximab or Ofatumumab) in Patients with Relapsed or Refractory CLL. 56th ASH Annual Meeting and Exposition, San Francisco, California.</citation>
  </results_reference>
  <results_reference>
    <citation>Furman R, Sharman J, et al. (2013). A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Idelalisib and Rituximab for Previously Treated Patients with CLL [Abstract LBA-6]. 55th ASH Annual Meeting and Exposition, New Orleans, Louisiana.</citation>
  </results_reference>
  <results_reference>
    <citation>Ghia P, Cheson BD, et al. (2016). Patterns of Idelalisib Treatment-Emergent Lymphocytosis in Patients with CLL or SLL [poster]. EHA 21st Congress, Copenhagen, Denmark.</citation>
  </results_reference>
  <results_reference>
    <citation>Ghia P, Coutre S, et al. (2016). Management of Transaminase Elevations Associated with Idelalisib [poster]. European Hematology Association (EHA) 21st Congress, Copenhagen, Denmark.</citation>
  </results_reference>
  <results_reference>
    <citation>Gopal AK, Davies AJ, et al. (2015). Idelalisib Monotherapy and Durable Responses in Patients with Relapsed or Refractory SLL. 57th ASH Annual Meeting and Exposition, Orlando, Florida.</citation>
  </results_reference>
  <results_reference>
    <citation>Kahl BS, Spurgeon SE, Furman RR, Flinn IW, Coutre SE, Brown JR, Benson DM, Byrd JC, Peterman S, Cho Y, Yu A, Godfrey WR, Wagner-Johnston ND. A phase 1 study of the PI3Kδ inhibitor idelalisib in patients with relapsed/refractory mantle cell lymphoma (MCL). Blood. 2014 May 29;123(22):3398-405. doi: 10.1182/blood-2013-11-537555. Epub 2014 Mar 10.</citation>
    <PMID>24615778</PMID>
  </results_reference>
  <results_reference>
    <citation>Leonard JP, Wagner-Johnston ND, et al. (2013). Combinations of the PI3Kδ Inhibitor Idelalisib (GS-1101) with Rituximab and/or Bendamustine are Tolerable and Highly Active in Patients with Previously Treated, Indolent non-Hodgkin Lymphoma: Updated Results from a Phase I Study [Presentation]. ASCO Annual Meeting, Chicago, Illinois.</citation>
  </results_reference>
  <results_reference>
    <citation>Martin P, Armas A, et al. (2015). Idelalisib Monotherapy and Durable Responses in Patients with Relapsed or Refractory Marginal Zone Lymphoma (MZL). 57th ASH Annual Meeting and Exposition, Orlando, Florida.</citation>
  </results_reference>
  <results_reference>
    <citation>O'Brien SM, Lamanna N, Kipps TJ, Flinn I, Zelenetz AD, Burger JA, Keating M, Mitra S, Holes L, Yu AS, Johnson DM, Miller LL, Kim Y, Dansey RD, Dubowy RL, Coutre SE. A phase 2 study of idelalisib plus rituximab in treatment-naïve older patients with chronic lymphocytic leukemia. Blood. 2015 Dec 17;126(25):2686-94. doi: 10.1182/blood-2015-03-630947. Epub 2015 Oct 15.</citation>
    <PMID>26472751</PMID>
  </results_reference>
  <results_reference>
    <citation>O'Brien SM, Lamanna N, et al. (2014). Update on a Phase 2 Study of Idelalisib in Combination with Rituximab in Treatment-Naive Patients ≥ 65 Years with CLL or SLL [Poster 1994]. 56th ASH Annual Meeting and Exposition, San Francisco, California.</citation>
  </results_reference>
  <results_reference>
    <citation>O'Brien SM, Lamanna N, et al. (2013). A Phase 2 Study of the Selective Phosphatidylinositol 3-Kinase Delta (PI3Kδ) Inhibitor Idelalisib (GS-1101) in Combination with Rituximab in Treatment-Naive Patients ≥ 65 Years with CLL or SLL [Presentation]. ASCO Annual Meeting, Chicago, Illinois.</citation>
  </results_reference>
  <results_reference>
    <citation>Spurgeon SE, Wagner-Johnston ND, et al. (2013). Final Results of a Phase 1 Study of Idelalisib, a Selective Inhibitor of Phosphatidylinositol 3-Kinase P110δ (PI3Kδ) in Patients with Relapsed or Refractory Mantle Cell Lymphoma [Presentation]. ASCO Annual Meeting, Chicago, Illinois.</citation>
  </results_reference>
  <results_reference>
    <citation>Wagner-Johnston ND, DeVos S, et al. (2013). Preliminary Results of PI3Kδ Inhibitor Idelalisib (GS-1101) Treatment in Combination with Everolimus, Bortezomib, or Bendamustine/Rituximab in Patients with Previously Treated Mantle Cell Lymphoma [Presentation]. ASCO Annual Meeting, Chicago, Illinois.</citation>
  </results_reference>
  <results_reference>
    <citation>Wierda W, Coutre S, et al. (2016). Management of Transaminase Elevations in Patients Receiving Idelalisib. ASCO Annual Meeting, Chicago, Illinois.</citation>
  </results_reference>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>March 17, 2010</study_first_submitted>
  <study_first_submitted_qc>March 18, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 22, 2010</study_first_posted>
  <results_first_submitted>June 7, 2019</results_first_submitted>
  <results_first_submitted_qc>August 22, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">August 28, 2019</results_first_posted>
  <last_update_submitted>August 22, 2019</last_update_submitted>
  <last_update_submitted_qc>August 22, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 28, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Idelalisib</keyword>
  <keyword>Chronic lymphocytic leukemia (CLL)</keyword>
  <keyword>Non-Hodgkin lymphoma (NHL)</keyword>
  <keyword>Phosphatidylinositol 3-kinase (PI3K)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Idelalisib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at http://www.gilead.com/research/disclosure-and-transparency.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_time_frame>18 months after study completion</ipd_time_frame>
    <ipd_access_criteria>A secured external environment with username, password, and RSA code.</ipd_access_criteria>
    <ipd_url>http://www.gilead.com/research/disclosure-and-transparency</ipd_url>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol: Original</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>January 22, 2010</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/14/NCT01090414/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol: Amendment 1</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>April 12, 2010</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/14/NCT01090414/Prot_001.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol: Amendment 2</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>October 28, 2013</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/14/NCT01090414/Prot_002.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol: Amendment 3</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>November 25, 2014</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/14/NCT01090414/Prot_003.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol: Amendment 4</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>March 25, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/14/NCT01090414/Prot_004.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol: Amendment 5</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>November 7, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/14/NCT01090414/Prot_005.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol: Amendment 6</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>August 28, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/14/NCT01090414/Prot_006.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 1, 2013</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/14/NCT01090414/SAP_007.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were enrolled at study sites in the United States. The first participant was screened on 22 March 2010. The last study visit occurred on 18 June 2018.</recruitment_details>
      <pre_assignment_details>Participants must have been enrolled in a previous Gilead-sponsored study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>101-02</title>
          <description>Participants with chronic lymphocytic leukemia (CLL), indolent non-Hodgkin lymphoma (iNHL), mantle cell lymphoma (MCL), diffuse large B-cell lymphoma (DLBCL), acute myeloid leukemia (AML), or multiple myeloma (MM) received idelalisib 50 mg, 100 mg, 150 mg, 200 mg, 300 mg, or 350 mg capsules twice daily during parent study 101-02 (NCT00710528, results reported within this record) and may have entered long-term safety extension study 101-99 to receive the same treatment.</description>
        </group>
        <group group_id="P2">
          <title>101-07</title>
          <description>Participants with CLL, iNHL, or MCL received idelalisib 100 mg or 150 mg tablets twice daily with or without rituximab, bendamustine, ofatumumab, fludarabine, everolimus, bortezomib, chlorambucil, and/or lenalidomide during parent study 101-07 (NCT01088048, results reported within this record) and may have entered long-term safety extension study 101-99 to receive the same treatment.</description>
        </group>
        <group group_id="P3">
          <title>101-08</title>
          <description>Participants with CLL or iNHL (specifically, small lymphocytic lymphoma (SLL)) received idelalisib 150 mg tablets twice daily with rituximab during parent study 101-08 (NCT01203930) and may have entered long-term safety extension study 101-99 to receive the same treatment. Note: Only participants from Cohort 1 were eligible to enter this Study 101-99, so Cohort 2 participants are not presented at all in this record.</description>
        </group>
        <group group_id="P4">
          <title>101-10</title>
          <description>Participants with iNHL received idelalisib 150 mg tablets twice daily during parent study 101-10 (NCT01306643) and may have entered long-term safety extension study 101-99 to receive the same treatment.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Parent Studies</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="191"/>
                <participants group_id="P2" count="241"/>
                <participants group_id="P3" count="64"/>
                <participants group_id="P4" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
                <participants group_id="P2" count="114"/>
                <participants group_id="P3" count="43"/>
                <participants group_id="P4" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="141"/>
                <participants group_id="P2" count="127"/>
                <participants group_id="P3" count="21"/>
                <participants group_id="P4" count="13"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Study 101-99</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="48">50 participants completed the parent study, but only 48 participants enrolled into Study 101-99.</participants>
                <participants group_id="P2" count="108">114 participants completed the parent study, but only 108 participants enrolled into Study 101-99.</participants>
                <participants group_id="P3" count="41">43 participants completed the parent study, but only 41 participants enrolled into Study 101-99.</participants>
                <participants group_id="P4" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="48"/>
                <participants group_id="P2" count="108"/>
                <participants group_id="P3" count="41"/>
                <participants group_id="P4" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Progressive Disease</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="48"/>
                <participants group_id="P3" count="10"/>
                <participants group_id="P4" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="28"/>
                <participants group_id="P3" count="18"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Investigator Request</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Sponsor Discontinued Study</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other (Unknown Reasons)</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrew Consent</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Participant Request</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Data presented includes baseline characteristic data for all participants who received any dose of idelalisib in the parent studies, excluding Cohort 2 participants from Study 101-08 who were not eligible to enroll into Study 101-99.</population>
      <group_list>
        <group group_id="B1">
          <title>101-02</title>
          <description>Participants with CLL, iNHL, MCL, DLBCL, AML, or MM received idelalisib 50 mg, 100 mg, 150 mg, 200 mg, 300 mg, or 350 mg capsules twice daily during parent study 101-02 (NCT00710528, results reported within this record) and may have entered long-term safety extension study 101-99 to receive the same treatment.</description>
        </group>
        <group group_id="B2">
          <title>101-07</title>
          <description>Participants with CLL, iNHL, or MCL received idelalisib 100 mg or 150 mg tablets twice daily with or without rituximab, bendamustine, ofatumumab, fludarabine, everolimus, bortezomib, chlorambucil, and/or lenalidomide during parent study 101-07 (NCT01088048, results reported within this record) and may have entered long-term safety extension study 101-99 to receive the same treatment.</description>
        </group>
        <group group_id="B3">
          <title>101-08</title>
          <description>Participants with CLL or iNHL (specifically, small lymphocytic lymphoma (SLL)) received idelalisib 150 mg tablets twice daily with rituximab during parent study 101-08 (NCT01203930) and may have entered long-term safety extension study 101-99 to receive the same treatment.</description>
        </group>
        <group group_id="B4">
          <title>101-10</title>
          <description>Participants with iNHL received idelalisib 150 mg tablets twice daily during parent study 101-10 (NCT01306643) and may have entered long-term safety extension study 101-99 to receive the same treatment.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="191"/>
            <count group_id="B2" value="241"/>
            <count group_id="B3" value="64"/>
            <count group_id="B4" value="18"/>
            <count group_id="B5" value="514"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt; 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="86"/>
                    <measurement group_id="B2" value="116"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="13"/>
                    <measurement group_id="B5" value="215"/>
                  </measurement_list>
                </category>
                <category>
                  <title>≥ 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="105"/>
                    <measurement group_id="B2" value="125"/>
                    <measurement group_id="B3" value="64"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="299"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="52"/>
                    <measurement group_id="B2" value="76"/>
                    <measurement group_id="B3" value="24"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="160"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="139"/>
                    <measurement group_id="B2" value="165"/>
                    <measurement group_id="B3" value="40"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="354"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="167"/>
                    <measurement group_id="B2" value="234"/>
                    <measurement group_id="B3" value="64"/>
                    <measurement group_id="B4" value="17"/>
                    <measurement group_id="B5" value="482"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Race</title>
              <category_list>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="160"/>
                    <measurement group_id="B2" value="209"/>
                    <measurement group_id="B3" value="61"/>
                    <measurement group_id="B4" value="12"/>
                    <measurement group_id="B5" value="442"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="21"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Diagnosis Status</title>
          <description>Diagnosis status of iNHL included the following types: follicular lymphoma (FL), small lymphocytic lymphoma (SLL), lymphoplasmacytic lymphoma/Waldenstrom’s Macroglobulinemia (LPL/WM), and marginal zone lymphoma (MZL).</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Chronic lymphocytic leukemia (CLL)</title>
                  <measurement_list>
                    <measurement group_id="B1" value="54"/>
                    <measurement group_id="B2" value="115"/>
                    <measurement group_id="B3" value="59"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="228"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Indolent non-Hodgkin lymphoma (iNHL)</title>
                  <measurement_list>
                    <measurement group_id="B1" value="64"/>
                    <measurement group_id="B2" value="86"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="17"/>
                    <measurement group_id="B5" value="172"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mantle cell lymphoma (MCL)</title>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="80"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Diffuse large B-cell lymphoma (DLBCL)</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Acute myeloid leukemia (AML)</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Multiple myeloma (MM)</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Missing</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Overall Response Rate</title>
        <description>Overall response rate (ORR) was defined as the percentage of participants who achieve complete response (CR), partial response (PR), or minor response (MR; for lymphoplasmacytic lymphoma/Waldenström's macroglobulinemia (LPL/WM) only).</description>
        <time_frame>Parent study baseline to end of study 101-99 (maximum: up to 91.2 months)</time_frame>
        <population>Data presented includes available data from both the parent studies and this Study 101-99. It was prespecified that data for Study 101-08 be combined for CLL and SLL participants.</population>
        <group_list>
          <group group_id="O1">
            <title>101-02 (AML)</title>
            <description>Participants with AML received idelalisib 50 mg, 100 mg, 150 mg, 200 mg, 300 mg, or 350 mg capsules twice daily during parent study 101-02 (NCT00710528, results reported within this record) and may have entered long-term safety extension study 101-99 to receive the same treatment.</description>
          </group>
          <group group_id="O2">
            <title>101-02 (CLL)</title>
            <description>Participants with CLL received idelalisib 50 mg, 100 mg, 150 mg, 200 mg, 300 mg, or 350 mg capsules twice daily during parent study 101-02 (NCT00710528, results reported within this record) and may have entered long-term safety extension study 101-99 to receive the same treatment.</description>
          </group>
          <group group_id="O3">
            <title>101-02 (DLBCL)</title>
            <description>Participants with DLBCL received idelalisib 50 mg, 100 mg, 150 mg, 200 mg, 300 mg, or 350 mg capsules twice daily during parent study 101-02 (NCT00710528, results reported within this record) and may have entered long-term safety extension study 101-99 to receive the same treatment.</description>
          </group>
          <group group_id="O4">
            <title>101-02 (iNHL)</title>
            <description>Participants with iNHL received idelalisib 50 mg, 100 mg, 150 mg, 200 mg, 300 mg, or 350 mg capsules twice daily during parent study 101-02 (NCT00710528, results reported within this record) and may have entered long-term safety extension study 101-99 to receive the same treatment.</description>
          </group>
          <group group_id="O5">
            <title>101-02 (MCL)</title>
            <description>Participants with MCL received idelalisib 50 mg, 100 mg, 150 mg, 200 mg, 300 mg, or 350 mg capsules twice daily during parent study 101-02 (NCT00710528, results reported within this record) and may have entered long-term safety extension study 101-99 to receive the same treatment.</description>
          </group>
          <group group_id="O6">
            <title>101-02 (MM)</title>
            <description>Participants with MM received idelalisib 50 mg, 100 mg, 150 mg, 200 mg, 300 mg, or 350 mg capsules twice daily during parent study 101-02 (NCT00710528, results reported within this record) and may have entered long-term safety extension study 101-99 to receive the same treatment.</description>
          </group>
          <group group_id="O7">
            <title>101-07 (CLL)</title>
            <description>Participants with CLL received idelalisib 100 mg or 150 mg tablets twice daily with or without rituximab, bendamustine, ofatumumab, fludarabine, chlorambucil, and/or lenalidomide during parent study 101-07 (NCT01088048, results reported within this record) and may have entered long-term safety extension study 101-99 to receive the same treatment.</description>
          </group>
          <group group_id="O8">
            <title>101-07 (iNHL)</title>
            <description>Participants with iNHL received idelalisib 100 mg or 150 mg tablets twice daily with or without rituximab, bendamustine, and/or lenalidomide during parent study 101-07 (NCT01088048, results reported within this record) and may have entered long-term safety extension study 101-99 to receive the same treatment.</description>
          </group>
          <group group_id="O9">
            <title>101-07 (MCL)</title>
            <description>Participants with MCL received idelalisib 100 mg or 150 mg tablets twice daily with or without rituximab, bendamustine, everolimus, bortezomib, and/or lenalidomide during parent study 101-07 (NCT01088048, results reported within this record) and may have entered long-term safety extension study 101-99 to receive the same treatment.</description>
          </group>
          <group group_id="O10">
            <title>101-08 (CLL or SLL)</title>
            <description>Participants with CLL or SLL received idelalisib 150 mg tablets twice daily with rituximab during parent study 101-08 (NCT01203930) and may have entered long-term safety extension study 101-99 to receive the same treatment.</description>
          </group>
          <group group_id="O11">
            <title>101-10 (iNHL)</title>
            <description>Participants with iNHL received idelalisib 150 mg tablets twice daily during parent study 101-10 (NCT01306643) and may have entered long-term safety extension study 101-99 to receive the same treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Response Rate</title>
          <description>Overall response rate (ORR) was defined as the percentage of participants who achieve complete response (CR), partial response (PR), or minor response (MR; for lymphoplasmacytic lymphoma/Waldenström's macroglobulinemia (LPL/WM) only).</description>
          <population>Data presented includes available data from both the parent studies and this Study 101-99. It was prespecified that data for Study 101-08 be combined for CLL and SLL participants.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="54"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="64"/>
                <count group_id="O5" value="40"/>
                <count group_id="O6" value="12"/>
                <count group_id="O7" value="115"/>
                <count group_id="O8" value="86"/>
                <count group_id="O9" value="40"/>
                <count group_id="O10" value="64"/>
                <count group_id="O11" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O2" value="57.4" lower_limit="43.2" upper_limit="70.8"/>
                    <measurement group_id="O3" value="11.1" lower_limit="0.3" upper_limit="48.2"/>
                    <measurement group_id="O4" value="48.4" lower_limit="35.8" upper_limit="61.3"/>
                    <measurement group_id="O5" value="40.0" lower_limit="24.9" upper_limit="56.7"/>
                    <measurement group_id="O6" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O7" value="81.7" lower_limit="73.5" upper_limit="88.3"/>
                    <measurement group_id="O8" value="82.6" lower_limit="72.9" upper_limit="89.9"/>
                    <measurement group_id="O9" value="57.5" lower_limit="40.9" upper_limit="73.0"/>
                    <measurement group_id="O10" value="96.9" lower_limit="89.2" upper_limit="99.6"/>
                    <measurement group_id="O11" value="44.4" lower_limit="21.5" upper_limit="69.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Who Experienced Any Treatment-Emergent Adverse Events</title>
        <time_frame>Parent study baseline to end of study 101-99 (maximum: up to 91.2 months) plus 30 days</time_frame>
        <population>Data presented includes data from both the parent studies and this Study 101-99. For this safety endpoint, data was prespecified to be combined.</population>
        <group_list>
          <group group_id="O1">
            <title>101-02</title>
            <description>Participants with CLL or iNHL received idelalisib 50 mg, 100 mg, 150 mg, 200 mg, 300 mg, or 350 mg capsules twice daily during parent study 101-02 (NCT00710528, results reported within this record) and entered long-term safety extension study 101-99 to receive the same treatment.</description>
          </group>
          <group group_id="O2">
            <title>101-07</title>
            <description>Participants with CLL, iNHL, or MCL received idelalisib 100 mg or 150 mg tablets twice daily with or without rituximab, bendamustine, ofatumumab, fludarabine, everolimus, bortezomib, chlorambucil, and/or lenalidomide during parent study 101-07 (NCT01088048, results reported within this record) and entered long-term safety extension study 101-99 to receive the same treatment.</description>
          </group>
          <group group_id="O3">
            <title>101-08</title>
            <description>Participants with CLL or SLL received idelalisib 150 mg tablets twice daily with rituximab during parent study 101-08 (NCT01203930) and entered long-term safety extension study 101-99 to receive the same treatment.</description>
          </group>
          <group group_id="O4">
            <title>101-10</title>
            <description>Participants with iNHL received idelalisib 150 mg tablets twice daily during parent study 101-10 (NCT01306643) and entered long-term safety extension study 101-99 to receive the same treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Experienced Any Treatment-Emergent Adverse Events</title>
          <population>Data presented includes data from both the parent studies and this Study 101-99. For this safety endpoint, data was prespecified to be combined.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="191"/>
                <count group_id="O2" value="241"/>
                <count group_id="O3" value="64"/>
                <count group_id="O4" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.4"/>
                    <measurement group_id="O2" value="98.8"/>
                    <measurement group_id="O3" value="100.0"/>
                    <measurement group_id="O4" value="94.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Response</title>
        <description>Duration of response (DOR) was defined as the interval from the first documentation of CR, PR, or MR (for LPL/WM) to the earlier of the first documentation of disease progression or death from any cause. DOR was analyzed using Kaplan-Meier (KM) estimates.</description>
        <time_frame>Parent study baseline to end of study 101-99 (maximum: up to 91.2 months)</time_frame>
        <population>Data presented includes available data from both the parent studies and this Study 101-99. It was prespecified that data for Study 101-08 be combined for CLL and SLL participants.</population>
        <group_list>
          <group group_id="O1">
            <title>101-02 (AML)</title>
            <description>Participants with AML received idelalisib 50 mg, 100 mg, 150 mg, 200 mg, 300 mg, or 350 mg capsules twice daily during parent study 101-02 (NCT00710528, results reported within this record) and may have entered long-term safety extension study 101-99 to receive the same treatment.</description>
          </group>
          <group group_id="O2">
            <title>101-02 (CLL)</title>
            <description>Participants with CLL received idelalisib 50 mg, 100 mg, 150 mg, 200 mg, 300 mg, or 350 mg capsules twice daily during parent study 101-02 (NCT00710528, results reported within this record) and may have entered long-term safety extension study 101-99 to receive the same treatment.</description>
          </group>
          <group group_id="O3">
            <title>101-02 (DLBCL)</title>
            <description>Participants with DLBCL received idelalisib 50 mg, 100 mg, 150 mg, 200 mg, 300 mg, or 350 mg capsules twice daily during parent study 101-02 (NCT00710528, results reported within this record) and may have entered long-term safety extension study 101-99 to receive the same treatment.</description>
          </group>
          <group group_id="O4">
            <title>101-02 (iNHL)</title>
            <description>Participants with iNHL received idelalisib 50 mg, 100 mg, 150 mg, 200 mg, 300 mg, or 350 mg capsules twice daily during parent study 101-02 (NCT00710528, results reported within this record) and may have entered long-term safety extension study 101-99 to receive the same treatment.</description>
          </group>
          <group group_id="O5">
            <title>101-02 (MCL)</title>
            <description>Participants with MCL received idelalisib 50 mg, 100 mg, 150 mg, 200 mg, 300 mg, or 350 mg capsules twice daily during parent study 101-02 (NCT00710528, results reported within this record) and may have entered long-term safety extension study 101-99 to receive the same treatment.</description>
          </group>
          <group group_id="O6">
            <title>101-02 (MM)</title>
            <description>Participants with MM received idelalisib 50 mg, 100 mg, 150 mg, 200 mg, 300 mg, or 350 mg capsules twice daily during parent study 101-02 (NCT00710528, results reported within this record) and may have entered long-term safety extension study 101-99 to receive the same treatment.</description>
          </group>
          <group group_id="O7">
            <title>101-07 (CLL)</title>
            <description>Participants with CLL received idelalisib 100 mg or 150 mg tablets twice daily with or without rituximab, bendamustine, ofatumumab, fludarabine, chlorambucil, and/or lenalidomide during parent study 101-07 (NCT01088048, results reported within this record) and may have entered long-term safety extension study 101-99 to receive the same treatment.</description>
          </group>
          <group group_id="O8">
            <title>101-07 (iNHL)</title>
            <description>Participants with iNHL received idelalisib 100 mg or 150 mg tablets twice daily with or without rituximab, bendamustine, and/or lenalidomide during parent study 101-07 (NCT01088048, results reported within this record) and may have entered long-term safety extension study 101-99 to receive the same treatment.</description>
          </group>
          <group group_id="O9">
            <title>101-07 (MCL)</title>
            <description>Participants with MCL received idelalisib 100 mg or 150 mg tablets twice daily with or without rituximab, bendamustine, everolimus, bortezomib, and/or lenalidomide during parent study 101-07 (NCT01088048, results reported within this record) and may have entered long-term safety extension study 101-99 to receive the same treatment.</description>
          </group>
          <group group_id="O10">
            <title>101-08 (CLL or SLL)</title>
            <description>Participants with CLL or SLL received idelalisib 150 mg tablets twice daily with rituximab during parent study 101-08 (NCT01203930) and may have entered long-term safety extension study 101-99 to receive the same treatment.</description>
          </group>
          <group group_id="O11">
            <title>101-10 (iNHL)</title>
            <description>Participants with iNHL received idelalisib 150 mg tablets twice daily during parent study 101-10 (NCT01306643) and may have entered long-term safety extension study 101-99 to receive the same treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Response</title>
          <description>Duration of response (DOR) was defined as the interval from the first documentation of CR, PR, or MR (for LPL/WM) to the earlier of the first documentation of disease progression or death from any cause. DOR was analyzed using Kaplan-Meier (KM) estimates.</description>
          <population>Data presented includes available data from both the parent studies and this Study 101-99. It was prespecified that data for Study 101-08 be combined for CLL and SLL participants.</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="54"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="64"/>
                <count group_id="O5" value="40"/>
                <count group_id="O6" value="12"/>
                <count group_id="O7" value="115"/>
                <count group_id="O8" value="86"/>
                <count group_id="O9" value="40"/>
                <count group_id="O10" value="64"/>
                <count group_id="O11" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="NA" upper_limit="NA">NA = No participants achieved complete or partial response.</measurement>
                    <measurement group_id="O2" value="21.2" lower_limit="8.1" upper_limit="30.4"/>
                    <measurement group_id="O3" value="NA" lower_limit="NA" upper_limit="NA">NA = not reached; Too few events to estimate the median and the lower and upper limits of the confidence interval.</measurement>
                    <measurement group_id="O4" value="18.4" lower_limit="10.9" upper_limit="32.4"/>
                    <measurement group_id="O5" value="2.7" lower_limit="1" upper_limit="8.1"/>
                    <measurement group_id="O6" value="NA" lower_limit="NA" upper_limit="NA">NA = No participants achieved complete or partial response.</measurement>
                    <measurement group_id="O7" value="26.6" lower_limit="18.5" upper_limit="44.1"/>
                    <measurement group_id="O8" value="42.9" lower_limit="20.5" upper_limit="83.3"/>
                    <measurement group_id="O9" value="9.3" lower_limit="5.6" upper_limit="37.5"/>
                    <measurement group_id="O10" value="63.8" lower_limit="54.0" upper_limit="NA">NA = Not reached; Too few events to estimate the upper limit of the confidence interval.</measurement>
                    <measurement group_id="O11" value="14.4" lower_limit="6.6" upper_limit="46.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression-Free Survival</title>
        <description>Progression-free survival (PFS) was defined as the interval from start of idelalisib treatment in the parent study to the earlier of the first documentation of disease progression or death from any cause. PFS was analyzed using KM estimates.</description>
        <time_frame>Parent study baseline to end of study 101-99 (maximum: up to 91.2 months)</time_frame>
        <population>Data presented includes available data from both the parent studies and this Study 101-99. It was prespecified that data for Study 101-08 be combined for CLL and SLL participants.</population>
        <group_list>
          <group group_id="O1">
            <title>101-02 (AML)</title>
            <description>Participants with AML received idelalisib 50 mg, 100 mg, 150 mg, 200 mg, 300 mg, or 350 mg capsules twice daily during parent study 101-02 (NCT00710528, results reported within this record) and may have entered long-term safety extension study 101-99 to receive the same treatment.</description>
          </group>
          <group group_id="O2">
            <title>101-02 (CLL)</title>
            <description>Participants with CLL received idelalisib 50 mg, 100 mg, 150 mg, 200 mg, 300 mg, or 350 mg capsules twice daily during parent study 101-02 (NCT00710528, results reported within this record) and may have entered long-term safety extension study 101-99 to receive the same treatment.</description>
          </group>
          <group group_id="O3">
            <title>101-02 (DLBCL)</title>
            <description>Participants with DLBCL received idelalisib 50 mg, 100 mg, 150 mg, 200 mg, 300 mg, or 350 mg capsules twice daily during parent study 101-02 (NCT00710528, results reported within this record) and may have entered long-term safety extension study 101-99 to receive the same treatment.</description>
          </group>
          <group group_id="O4">
            <title>101-02 (iNHL)</title>
            <description>Participants with iNHL received idelalisib 50 mg, 100 mg, 150 mg, 200 mg, 300 mg, or 350 mg capsules twice daily during parent study 101-02 (NCT00710528, results reported within this record) and may have entered long-term safety extension study 101-99 to receive the same treatment.</description>
          </group>
          <group group_id="O5">
            <title>101-02 (MCL)</title>
            <description>Participants with MCL received idelalisib 50 mg, 100 mg, 150 mg, 200 mg, 300 mg, or 350 mg capsules twice daily during parent study 101-02 (NCT00710528, results reported within this record) and may have entered long-term safety extension study 101-99 to receive the same treatment.</description>
          </group>
          <group group_id="O6">
            <title>101-02 (MM)</title>
            <description>Participants with MM received idelalisib 50 mg, 100 mg, 150 mg, 200 mg, 300 mg, or 350 mg capsules twice daily during parent study 101-02 (NCT00710528, results reported within this record) and may have entered long-term safety extension study 101-99 to receive the same treatment.</description>
          </group>
          <group group_id="O7">
            <title>101-07 (CLL)</title>
            <description>Participants with CLL received idelalisib 100 mg or 150 mg tablets twice daily with or without rituximab, bendamustine, ofatumumab, fludarabine, chlorambucil, and/or lenalidomide during parent study 101-07 (NCT01088048, results reported within this record) and may have entered long-term safety extension study 101-99 to receive the same treatment.</description>
          </group>
          <group group_id="O8">
            <title>101-07 (iNHL)</title>
            <description>Participants with iNHL received idelalisib 100 mg or 150 mg tablets twice daily with or without rituximab, bendamustine, and/or lenalidomide during parent study 101-07 (NCT01088048, results reported within this record) and may have entered long-term safety extension study 101-99 to receive the same treatment.</description>
          </group>
          <group group_id="O9">
            <title>101-07 (MCL)</title>
            <description>Participants with MCL received idelalisib 100 mg or 150 mg tablets twice daily with or without rituximab, bendamustine, everolimus, bortezomib, and/or lenalidomide during parent study 101-07 (NCT01088048, results reported within this record) and may have entered long-term safety extension study 101-99 to receive the same treatment.</description>
          </group>
          <group group_id="O10">
            <title>101-08 (CLL or SLL)</title>
            <description>Participants with CLL or SLL received idelalisib 150 mg tablets twice daily with rituximab during parent study 101-08 (NCT01203930) and may have entered long-term safety extension study 101-99 to receive the same treatment.</description>
          </group>
          <group group_id="O11">
            <title>101-10 (iNHL)</title>
            <description>Participants with iNHL received idelalisib 150 mg tablets twice daily during parent study 101-10 (NCT01306643) and may have entered long-term safety extension study 101-99 to receive the same treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-Free Survival</title>
          <description>Progression-free survival (PFS) was defined as the interval from start of idelalisib treatment in the parent study to the earlier of the first documentation of disease progression or death from any cause. PFS was analyzed using KM estimates.</description>
          <population>Data presented includes available data from both the parent studies and this Study 101-99. It was prespecified that data for Study 101-08 be combined for CLL and SLL participants.</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="54"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="64"/>
                <count group_id="O5" value="40"/>
                <count group_id="O6" value="12"/>
                <count group_id="O7" value="115"/>
                <count group_id="O8" value="86"/>
                <count group_id="O9" value="40"/>
                <count group_id="O10" value="64"/>
                <count group_id="O11" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9" lower_limit="0.4" upper_limit="1"/>
                    <measurement group_id="O2" value="15.8" lower_limit="5.6" upper_limit="39.6"/>
                    <measurement group_id="O3" value="1.5" lower_limit="0.3" upper_limit="4.1"/>
                    <measurement group_id="O4" value="7.6" lower_limit="3.7" upper_limit="17.7"/>
                    <measurement group_id="O5" value="3.7" lower_limit="2.7" upper_limit="8.2"/>
                    <measurement group_id="O6" value="1" lower_limit="0.9" upper_limit="1.8"/>
                    <measurement group_id="O7" value="26.1" lower_limit="19.0" upper_limit="36.8"/>
                    <measurement group_id="O8" value="32.8" lower_limit="22.0" upper_limit="81.3"/>
                    <measurement group_id="O9" value="11.1" lower_limit="3.4" upper_limit="12.9"/>
                    <measurement group_id="O10" value="65.6" lower_limit="55.8" upper_limit="NA">NA = Not reached; Too few events to estimate the upper limit of the confidence interval.</measurement>
                    <measurement group_id="O11" value="10.2" lower_limit="2.8" upper_limit="19.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival</title>
        <description>Overall survival (OS) was defined as the interval from the start of study treatment in the parent study to death from any cause. OS was analyzed using KM estimates.</description>
        <time_frame>Parent study baseline to end of study 101-99 (maximum: up to 91.2 months)</time_frame>
        <population>Data presented includes available data from both the parent studies and this Study 101-99. It was prespecified that data for Study 101-08 be combined for CLL and SLL participants.</population>
        <group_list>
          <group group_id="O1">
            <title>101-02 (AML)</title>
            <description>Participants with AML received idelalisib 50 mg, 100 mg, 150 mg, 200 mg, 300 mg, or 350 mg capsules twice daily during parent study 101-02 (NCT00710528, results reported within this record) and may have entered long-term safety extension study 101-99 to receive the same treatment.</description>
          </group>
          <group group_id="O2">
            <title>101-02 (CLL)</title>
            <description>Participants with CLL received idelalisib 50 mg, 100 mg, 150 mg, 200 mg, 300 mg, or 350 mg capsules twice daily during parent study 101-02 (NCT00710528, results reported within this record) and may have entered long-term safety extension study 101-99 to receive the same treatment.</description>
          </group>
          <group group_id="O3">
            <title>101-02 (DLBCL)</title>
            <description>Participants with DLBCL received idelalisib 50 mg, 100 mg, 150 mg, 200 mg, 300 mg, or 350 mg capsules twice daily during parent study 101-02 (NCT00710528, results reported within this record) and may have entered long-term safety extension study 101-99 to receive the same treatment.</description>
          </group>
          <group group_id="O4">
            <title>101-02 (iNHL)</title>
            <description>Participants with iNHL received idelalisib 50 mg, 100 mg, 150 mg, 200 mg, 300 mg, or 350 mg capsules twice daily during parent study 101-02 (NCT00710528, results reported within this record) and may have entered long-term safety extension study 101-99 to receive the same treatment.</description>
          </group>
          <group group_id="O5">
            <title>101-02 (MCL)</title>
            <description>Participants with MCL received idelalisib 50 mg, 100 mg, 150 mg, 200 mg, 300 mg, or 350 mg capsules twice daily during parent study 101-02 (NCT00710528, results reported within this record) and may have entered long-term safety extension study 101-99 to receive the same treatment.</description>
          </group>
          <group group_id="O6">
            <title>101-02 (MM)</title>
            <description>Participants with MM received idelalisib 50 mg, 100 mg, 150 mg, 200 mg, 300 mg, or 350 mg capsules twice daily during parent study 101-02 (NCT00710528, results reported within this record) and may have entered long-term safety extension study 101-99 to receive the same treatment.</description>
          </group>
          <group group_id="O7">
            <title>101-07 (CLL)</title>
            <description>Participants with CLL received idelalisib 100 mg or 150 mg tablets twice daily with or without rituximab, bendamustine, ofatumumab, fludarabine, chlorambucil, and/or lenalidomide during parent study 101-07 (NCT01088048, results reported within this record) and may have entered long-term safety extension study 101-99 to receive the same treatment.</description>
          </group>
          <group group_id="O8">
            <title>101-07 (iNHL)</title>
            <description>Participants with iNHL received idelalisib 100 mg or 150 mg tablets twice daily with or without rituximab, bendamustine, and/or lenalidomide during parent study 101-07 (NCT01088048, results reported within this record) and may have entered long-term safety extension study 101-99 to receive the same treatment.</description>
          </group>
          <group group_id="O9">
            <title>101-07 (MCL)</title>
            <description>Participants with MCL received idelalisib 100 mg or 150 mg tablets twice daily with or without rituximab, bendamustine, everolimus, bortezomib, and/or lenalidomide during parent study 101-07 (NCT01088048, results reported within this record) and may have entered long-term safety extension study 101-99 to receive the same treatment.</description>
          </group>
          <group group_id="O10">
            <title>101-08 (CLL or SLL)</title>
            <description>Participants with CLL or SLL received idelalisib 150 mg tablets twice daily with rituximab during parent study 101-08 (NCT01203930) and may have entered long-term safety extension study 101-99 to receive the same treatment.</description>
          </group>
          <group group_id="O11">
            <title>101-10 (iNHL)</title>
            <description>Participants with iNHL received idelalisib 150 mg tablets twice daily during parent study 101-10 (NCT01306643) and may have entered long-term safety extension study 101-99 to receive the same treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <description>Overall survival (OS) was defined as the interval from the start of study treatment in the parent study to death from any cause. OS was analyzed using KM estimates.</description>
          <population>Data presented includes available data from both the parent studies and this Study 101-99. It was prespecified that data for Study 101-08 be combined for CLL and SLL participants.</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="54"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="64"/>
                <count group_id="O5" value="40"/>
                <count group_id="O6" value="12"/>
                <count group_id="O7" value="115"/>
                <count group_id="O8" value="86"/>
                <count group_id="O9" value="40"/>
                <count group_id="O10" value="64"/>
                <count group_id="O11" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="NA" upper_limit="NA">NA = not reached; Too few events to estimate the median and the lower and upper limits of the confidence interval.</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="39.7" upper_limit="NA">NA = not reached; Too few events to estimate the median and upper limit of the confidence interval.</measurement>
                    <measurement group_id="O3" value="NA" lower_limit="NA" upper_limit="NA">NA = not reached; Too few events to estimate the median and the lower and upper limits of the confidence interval.</measurement>
                    <measurement group_id="O4" value="NA" lower_limit="NA" upper_limit="NA">NA = not reached; Too few events to estimate the median and the lower and upper limits of the confidence interval.</measurement>
                    <measurement group_id="O5" value="NA" lower_limit="NA" upper_limit="NA">NA = not reached; Too few events to estimate the median and the lower and upper limits of the confidence interval.</measurement>
                    <measurement group_id="O6" value="5.2" lower_limit="1.2" upper_limit="5.2"/>
                    <measurement group_id="O7" value="NA" lower_limit="50.2" upper_limit="NA">NA = not reached; Too few events to estimate the median and upper limit of the confidence interval.</measurement>
                    <measurement group_id="O8" value="NA" lower_limit="NA" upper_limit="NA">NA = not reached; Too few events to estimate the median and the lower and upper limits of the confidence interval.</measurement>
                    <measurement group_id="O9" value="NA" lower_limit="NA" upper_limit="NA">NA = not reached; Too few events to estimate the median and the lower and upper limits of the confidence interval.</measurement>
                    <measurement group_id="O10" value="NA" lower_limit="66.3" upper_limit="NA">NA = not reached; Too few events to estimate the median and upper limit of the confidence interval.</measurement>
                    <measurement group_id="O11" value="NA" lower_limit="10.3" upper_limit="NA">NA = not reached; Too few events to estimate the median and upper limit of the confidence interval.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Response</title>
        <description>Time to response (TTR) was defined as the interval from start of study treatment to the first documentation of CR, PR, or MR (for LPL/WM). Analysis only includes participants who achieved complete or partial response (or minor response for LPL/WM participants). No participants in the 101-02 (AML and MM) groups achieved a complete or partial response.</description>
        <time_frame>Parent study baseline to end of study 101-99 (maximum: up to 91.2 months)</time_frame>
        <population>Data presented includes available data from both the parent studies and this Study 101-99. It was prespecified that data for Study 101-08 be combined for CLL and SLL participants.</population>
        <group_list>
          <group group_id="O1">
            <title>101-02 (AML)</title>
            <description>Participants with AML received idelalisib 50 mg, 100 mg, 150 mg, 200 mg, 300 mg, or 350 mg capsules twice daily during parent study 101-02 (NCT00710528, results reported within this record) and may have entered long-term safety extension study 101-99 to receive the same treatment.</description>
          </group>
          <group group_id="O2">
            <title>101-02 (CLL)</title>
            <description>Participants with CLL received idelalisib 50 mg, 100 mg, 150 mg, 200 mg, 300 mg, or 350 mg capsules twice daily during parent study 101-02 (NCT00710528, results reported within this record) and may have entered long-term safety extension study 101-99 to receive the same treatment.</description>
          </group>
          <group group_id="O3">
            <title>101-02 (DLBCL)</title>
            <description>Participants with DLBCL received idelalisib 50 mg, 100 mg, 150 mg, 200 mg, 300 mg, or 350 mg capsules twice daily during parent study 101-02 (NCT00710528, results reported within this record) and may have entered long-term safety extension study 101-99 to receive the same treatment.</description>
          </group>
          <group group_id="O4">
            <title>101-02 (iNHL)</title>
            <description>Participants with iNHL received idelalisib 50 mg, 100 mg, 150 mg, 200 mg, 300 mg, or 350 mg capsules twice daily during parent study 101-02 (NCT00710528, results reported within this record) and may have entered long-term safety extension study 101-99 to receive the same treatment.</description>
          </group>
          <group group_id="O5">
            <title>101-02 (MCL)</title>
            <description>Participants with MCL received idelalisib 50 mg, 100 mg, 150 mg, 200 mg, 300 mg, or 350 mg capsules twice daily during parent study 101-02 (NCT00710528, results reported within this record) and may have entered long-term safety extension study 101-99 to receive the same treatment.</description>
          </group>
          <group group_id="O6">
            <title>101-02 (MM)</title>
            <description>Participants with MM received idelalisib 50 mg, 100 mg, 150 mg, 200 mg, 300 mg, or 350 mg capsules twice daily during parent study 101-02 (NCT00710528, results reported within this record) and may have entered long-term safety extension study 101-99 to receive the same treatment.</description>
          </group>
          <group group_id="O7">
            <title>101-07 (CLL)</title>
            <description>Participants with CLL received idelalisib 100 mg or 150 mg tablets twice daily with or without rituximab, bendamustine, ofatumumab, fludarabine, chlorambucil, and/or lenalidomide during parent study 101-07 (NCT01088048, results reported within this record) and may have entered long-term safety extension study 101-99 to receive the same treatment.</description>
          </group>
          <group group_id="O8">
            <title>101-07 (iNHL)</title>
            <description>Participants with iNHL received idelalisib 100 mg or 150 mg tablets twice daily with or without rituximab, bendamustine, and/or lenalidomide during parent study 101-07 (NCT01088048, results reported within this record) and may have entered long-term safety extension study 101-99 to receive the same treatment.</description>
          </group>
          <group group_id="O9">
            <title>101-07 (MCL)</title>
            <description>Participants with MCL received idelalisib 100 mg or 150 mg tablets twice daily with or without rituximab, bendamustine, everolimus, bortezomib, and/or lenalidomide during parent study 101-07 (NCT01088048, results reported within this record) and may have entered long-term safety extension study 101-99 to receive the same treatment.</description>
          </group>
          <group group_id="O10">
            <title>101-08 (CLL or SLL)</title>
            <description>Participants with CLL or SLL received idelalisib 150 mg tablets twice daily with rituximab during parent study 101-08 (NCT01203930) and may have entered long-term safety extension study 101-99 to receive the same treatment.</description>
          </group>
          <group group_id="O11">
            <title>101-10 (iNHL)</title>
            <description>Participants iNHL received idelalisib 150 mg tablets twice daily during parent study 101-10 (NCT01306643) and may have entered long-term safety extension study 101-99 to receive the same treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Response</title>
          <description>Time to response (TTR) was defined as the interval from start of study treatment to the first documentation of CR, PR, or MR (for LPL/WM). Analysis only includes participants who achieved complete or partial response (or minor response for LPL/WM participants). No participants in the 101-02 (AML and MM) groups achieved a complete or partial response.</description>
          <population>Data presented includes available data from both the parent studies and this Study 101-99. It was prespecified that data for Study 101-08 be combined for CLL and SLL participants.</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="31"/>
                <count group_id="O3" value="1"/>
                <count group_id="O4" value="31"/>
                <count group_id="O5" value="16"/>
                <count group_id="O6" value="0"/>
                <count group_id="O7" value="94"/>
                <count group_id="O8" value="71"/>
                <count group_id="O9" value="23"/>
                <count group_id="O10" value="62"/>
                <count group_id="O11" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="1.9" lower_limit="1.0" upper_limit="7.5"/>
                    <measurement group_id="O3" value="4.0" lower_limit="4.0" upper_limit="4.0"/>
                    <measurement group_id="O4" value="1.3" lower_limit="1.0" upper_limit="3.7"/>
                    <measurement group_id="O5" value="1.1" lower_limit="1.0" upper_limit="1.9"/>
                    <measurement group_id="O7" value="1.9" lower_limit="1.9" upper_limit="1.9"/>
                    <measurement group_id="O8" value="1.9" lower_limit="1.9" upper_limit="3.0"/>
                    <measurement group_id="O9" value="1.9" lower_limit="1.9" upper_limit="2.0"/>
                    <measurement group_id="O10" value="1.9" lower_limit="1.9" upper_limit="1.9"/>
                    <measurement group_id="O11" value="2.7" lower_limit="2.6" upper_limit="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>First dose date in parent study to end of study 101-99 (maximum: up to 91.2 months) plus 30 days</time_frame>
      <desc>Adverse events presented occurred during either the parent studies or Study 101-99. Because Study 101-99 was a long-term extension study, the adverse event data was prespecified to be combined and reported based on the participation in the parent studies.</desc>
      <group_list>
        <group group_id="E1">
          <title>101-02</title>
          <description>Participants with CLL, iNHL, MCL, DLBCL, AML, or MM received idelalisib 50 mg, 100 mg, 150 mg, 200 mg, 300 mg, or 350 mg capsules twice daily during parent study 101-02 (NCT00710528, results reported within this record) and may have entered the long-term safety extension study 101-99 to receive the same treatment.</description>
        </group>
        <group group_id="E2">
          <title>101-07</title>
          <description>Participants with CLL, iNHL, or MCL received idelalisib 100 mg or 150 mg tablets twice daily with or without rituximab, bendamustine, ofatumumab, fludarabine, everolimus, bortezomib, chlorambucil, and/or lenalidomide during parent study 101-07 (NCT01088048, results reported within this record) and may have entered long-term safety extension study 101-99 to receive the same treatment.</description>
        </group>
        <group group_id="E3">
          <title>101-08</title>
          <description>Participants with CLL or SLL received idelalisib 150 mg tablets twice daily with rituximab during parent study 101-08 (NCT01203930) and may have entered long-term safety extension study 101-99 to receive the same treatment.</description>
        </group>
        <group group_id="E4">
          <title>101-10</title>
          <description>Participants with iNHL received idelalisib 150 mg tablets twice daily during parent study 101-10 (NCT01306643) and may have entered long-term safety extension study 101-99 to receive the same treatment.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 21.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="45"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="100" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="165" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="45" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Aplasia pure red cell</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Autoimmune haemolytic anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Autoimmune neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Coombs positive haemolytic anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Haemolytic anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Immune thrombocytopenic purpura</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Atrioventricular block second degree</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Mitral valve incompetence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Pulseless electrical activity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Endocrine disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Retinal detachment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Uveitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Colitis ischaemic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Colitis microscopic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Crohn's disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Diarrhoea haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Gastrointestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Gastrointestinal perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Gingival bleeding</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Large intestinal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Mouth haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Neutropenic colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Odynophagia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Oesophagitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Peptic ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Retroperitoneal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Umbilical hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Generalised oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Impaired healing</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Mucosal inflammation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Multiple organ dysfunction syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Cholecystitis chronic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Hepatic failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Hepatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abdominal wall infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Abscess neck</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Arthritis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Aspergillus infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Atypical pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Bacterial infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Bacterial sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Bronchiolitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Bronchopulmonary aspergillosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Candida infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Cellulitis staphylococcal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Cerebral aspergillosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Clostridium difficile colitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Clostridium difficile infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Corynebacterium bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Cytomegalovirus gastrointestinal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Cytomegalovirus infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Cytomegalovirus viraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Encephalitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Endophthalmitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Enterococcal bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Enterocolitis infectious</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Escherichia bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Escherichia sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Folliculitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Gangrene</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Gastroenteritis salmonella</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Groin abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Herpes zoster disseminated</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Herpes zoster pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Histoplasmosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Human herpesvirus 6 infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Hydrocele male infected</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Listeria sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Listeriosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Meningitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Meningitis aseptic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Meningitis enterococcal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Mycobacterium avium complex infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Neutropenic infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Neutropenic sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Oesophageal candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Ophthalmic herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Oral candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Perirectal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Pneumococcal bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Pneumococcal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Pneumocystis jirovecii infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Pneumocystis jirovecii pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="40" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Pneumonia bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Pneumonia fungal</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Pneumonia haemophilus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Pneumonia influenzal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Pneumonia pneumococcal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Pneumonia pseudomonal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Pseudomonal bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Pseudomonas infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Respiratory syncytial virus infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Sepsis syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Sinusitis fungal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Staphylococcal bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Staphylococcal infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Streptococcal bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Systemic candida</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Tooth infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Vaginal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Vulvovaginitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Arterial injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Infusion related reaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Pelvic fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Post procedural haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Subarachnoid haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Blood lactate dehydrogenase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Blood uric acid increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Hepatic enzyme increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>International normalised ratio increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Liver function test increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Transaminases increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Failure to thrive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Fluid retention</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Hypercalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Hyperuricaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Lactic acidosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Malnutrition</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Tumour lysis syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Flank pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Polyarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Rhabdomyolysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Acute myeloid leukaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Chronic myeloid leukaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Endometrial adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Malignant pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Mantle cell lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Metastatic malignant melanoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Myelodysplastic syndrome</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Non-Hodgkin's lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Oesophageal squamous cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Rectal adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Renal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Richter's syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of lung</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Balance disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Cerebral ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Embolic stroke</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Haemorrhage intracranial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Lethargy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Normal pressure hydrocephalus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Mental status changes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Hydronephrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Urethral obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Urinary tract obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Pelvic pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Testicular pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Vaginal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute lung injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Atelectasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Bronchial secretion retention</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Bronchiectasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Organising pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Pleuritic pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Pulmonary fibrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Pulmonary haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Respiratory distress</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Upper airway obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Angioedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Drug eruption</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Erythema multiforme</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Rash erythematous</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Rash maculo-papular</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Skin ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Embolism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Jugular vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Peripheral vascular disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Subclavian vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Vasculitis necrotising</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 21.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="183" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="236" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="63" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="16" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="48" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="102" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="48" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Atrial tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Blepharospasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Chalazion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Conjunctival hyperaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Keratitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Photopsia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="49" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="58" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="106" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="36" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Dyschezia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Gastrointestinal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Haemorrhoidal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Lip discolouration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="44" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="81" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="24" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Oral pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Paraesthesia oral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="40" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="63" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="85" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Mucosal inflammation</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Oedema</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="49" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="92" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="26" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperbilirubinaemia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Candida infection</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Hordeolum</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Pneumonia viral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="38" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Infusion related reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="52" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="47" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Blood alkaline phosphatase increased</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Blood lactate dehydrogenase increased</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Blood phosphorus increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Blood uric acid increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Glomerular filtration rate decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Hepatic enzyme increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Liver function test increased</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Transaminases increased</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="41" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Hyperuricaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Hypomagnesaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Hypophosphataemia</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Flank pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Haemarthrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Joint stiffness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Hypersomnia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Lethargy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Mental impairment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Neuropathy peripheral</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Emotional disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Chromaturia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Nocturia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Pollakiuria</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="81" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Dysphonia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="42" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Hypopnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Productive cough</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Sinus pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Acne</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Exfoliative rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Hyperkeratosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Night sweats</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="65" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="24" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Skin fissures</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Hot flush</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:
The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or
The study has been completed at all study sites for at least 2 years</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Gilead Clinical Study Information Center</name_or_title>
      <organization>Gilead Sciences</organization>
      <phone>1-833-445-3230 (GILEAD-0)</phone>
      <email>GileadClinicalTrials@gilead.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

